NCT03575806View on ClinicalTrials.gov

Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 9, 2017

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Hepatocellular CarcinomaMalignant Neoplasm
Interventions
COMBINATION_PRODUCT

TACE plus autologous Tcm immunotherapy

"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."

PROCEDURE

TACE

TACE:transcatheter arterial chemoembolization.

Trial Locations (1)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Newish Technology (Beijing) Co., Ltd.

INDUSTRY

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT03575806 - Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection | Biotech Hunter | Biotech Hunter